OncoMatch/Clinical Trials/NCT06169371
Abemaciclib Dose Escalation to Maintain Intensity (ADE-MI)
Is NCT06169371 recruiting? Yes, currently enrolling (Jun 2026). This Phase 4 trial studies multiple treatments including Abemaciclib and Abemaciclib for breast cancer.
Treatment: Abemaciclib · Abemaciclib · Abemaciclib — This is a post-marketing single arm, phase IV trial in which patients with high-risk early-stage HR+HER2- breast cancer will receive adjuvant abemaciclib in combination with endocrine therapy (ET) After study intervention, participants will remain on combination abemaciclib + ET at the discretion of their treating providers
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Cancer type
Breast Carcinoma
Biomarker criteria
Required: HER2 (ERBB2) negative
Required: ESR1 positive
Disease stage
Required: Stage EARLY-STAGE
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Illinois · Chicago, Illinois
- Iowa Holden Comprehensive Cancer Center · Iowa City, Iowa
- Ohio State University Comprehensive Cancer Center · Columbus, Ohio
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06169371 currently recruiting?
Yes, this trial is currently recruiting patients.
Does this trial require ERBB2?
Yes, ERBB2 negative is a required biomarker for enrollment.
Does this trial require ESR1?
Yes, ESR1 positive is a required biomarker for enrollment.
What disease stage is eligible?
Stage EARLY-STAGE is required.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages